Product
TPST-1495
Aliases
TPST-1495 once daily or on intermittent schedule, TPST-1495 twice daily
2 clinical trials
10 indications
Indication
Solid TumorIndication
Colorectal CancerIndication
Lung CancerIndication
Squamous Cell Carcinoma of Head and NeckIndication
Bladder CancerIndication
Endometrial CancerIndication
Esophageal CancerIndication
Stomach AdenocarcinomaIndication
Solid Tumors with PIK3CA MutationIndication
Endometrial CarcinomaClinical trial
Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase 2 Pilot Window of Opportunity Study of the EP2 and EP4 Receptors Inhibitor TPST-1495 in Patients With Endometrial Cancer or Colorectal Cancer Planning to Undergo Surgical TherapyStatus: Recruiting, Estimated PCD: 2025-04-30